ReviewMicroorganisms2025
Carbapenem-Resistant
Review in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Distribution of mrk genes among uopathogenic Klebsiella pneumoniae.Journal of applied genetics · 2026Article
- Molecular and Structural Insights ofAntibiotics (Basel, Switzerland) · 2026Article
- Whole-Genome Analysis Reveals Antimicrobial Resistance and Population Structure of Environmental and VeterinaryInternational journal of molecular sciences · 2026Article
- Detection ofMicrobiologyOpen · 2026Article
- Genotypic and Phenotypic Resistance Profiles of InvasiveMicroorganisms · 2026Article
- Characterization ofAntibiotics (Basel, Switzerland) · 2026Article
- Insights into antimicrobial resistance: dissemination and molecular epidemiology of carbapenemase and AmpC genes in uropathogenic Escherichia coli.BMC microbiology · 2026Article
- From Environmental Organism to Nosocomial Threat:Antibiotics (Basel, Switzerland) · 2026Review
- Comparative genomic and resistance characterization of ST2 and ST164 carbapenem-resistantMicrobial genomics · 2026Article
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- Clinical risk factors for multidrug-resistant organism infections in postoperative gastric cancer patients: an ICU-based retrospective analysis.BMC infectious diseases · 2026Article
- Six Years ofAntibiotics (Basel, Switzerland) · 2026Article
- Novel triphenylphosphonium-hydrazone salts: integrated experimental and computational insights into AChE inhibition and resistance-overcoming antimicrobial and antibiofilm potential.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Distribution of acquired carbapenemase genes among uropathogenic Escherichia coli.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Analysis of Genetic Characteristics, Biofilm Formation Ability, and Mortality Risk Factors in Patients Infected with Carbapenem-ResistantInfection and drug resistance · 2026Article
- Article
- Prevalence and antimicrobial resistance ofFrontiers in microbiology · 2026Article
- Distribution of antimicrobial resistance genes and virulence genes in different genotypes of Acinetobacter baumannii.BMC infectious diseases · 2025Article
- Investigation and control of a suspected outbreak of carbapenem-resistantFrontiers in public health · 2025Article
- In Vitro Activity of Ceftazidime/Avibactam Against Multidrug-Resistant Gram-Negative Bacilli in Niger.Nigerian medical journal : journal of the Nigeria Medical AssociationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.